Daily pill doubles survival time for pancreatic cancer patients
A new drug called daraxonrasib has been shown to nearly double the survival time for patients with advanced pancreatic cancer by targeting the mutated KRAS gene. Clinical trials involving 500 patients demonstrated significantly better outcomes compared to traditional chemotherapy.
Why it matters
Pancreatic cancer is notoriously difficult to treat, and this breakthrough represents a major advancement in oncology and patient care.
Daily pill daraxonrasib doubles survival time for pancreatic cancer patients
The article is a factual report on medical research findings and clinical trial results.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in